Insider Buy ·Filed Aug 19, 2026

ASND

Ascendis Pharma A/S
NEUTRAL
Impact 3/10
Horizonweeks Processed1mo ago SEC0001610717-26-000360
Insider cluster: 1 insiders, $493K total
Actionable Insight • Neutral

The $493K director buy is too small to be a standalone signal. Monitor for larger insider purchases, especially from C-suite executives, or a catalyst event (e.g., FDA decision, pipeline update) that could justify a more material position. The strong analyst consensus already prices in bullish expectations.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
ASND ▼ -7.93% at T+20d
NEUTRAL call ✗ call lost -7.93% · α vs SPY -5.98% · entry $259.62 → $239.04
Next anchor: T+60d in 6w
Latest observation: T+28 -7.16% FF3 residual α
Entry anchored
Aug 18, 2026
via day open
T+1d
-1.85%
call -1.85% · α -1.01%
$254.81
settled 6w ago
T+5d
-3.61%
call -3.61% · α -3.22%
$250.25
settled 5w ago
T+20d
-7.93%
call -7.93% · α -5.98%
$239.04
settled 16d ago
T+60d
—
call — · α —
—
in 6w

Price Chart

Loading chart...

Executive Summary

Director Jean Jacques Bienaime purchased $493K of ASND stock in two open-market transactions on August 14, 2026, at ~$246/share. This is a modest conviction buy from a director, representing ~0.003% of the $15.3B market cap — a trivial dollar amount relative to company size. The buy is notable only for its timing alongside strong analyst consensus (96% bullish), but the absolute dollar value is too small to carry a meaningful signal.

Key Financial Metrics

Direction
buying
Total Value
$493.0K
Insiders
1

Key Facts

  • Director Jean Jacques Bienaime bought 2,000 shares total for $493K on August 14, 2026
  • Purchases were at ~$245.85 and ~$246.91 per share
  • Total buy represents ~0.003% of ASND's $15.3B market cap
  • Analyst consensus is 96% bullish (25 Buy, 1 Hold, 0 Sell)
  • No C-suite insider participated in this buy

Financial Impact

$493K total insider purchase, negligible relative to $15.3B market cap

insider ownership

Risk Factors

  • Director buy is trivial relative to market cap — may be a routine portfolio adjustment
  • No C-suite participation reduces signal strength
  • Historical calibration shows score-6+ reports on ASND have only ~42-46% win rate at T+20

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001610717-26-000360
29 reports for ASND
Performance horizon
85% Hit rate 17 of 20 directional calls best @ T+20▲ +26.62%Jun 2, 2026
Filters
Rows
Reports for ASND — sortable, filterable
TypeNow
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 2/10
$260.81 $247.69▼ −5.03%▼ −4.37%$227.23 (−12.88%)
Aug 31, 2026
4w ago
6-K
NEUTRAL ★ 6/10
$260.25 $260.81▲ +0.22%▲ +0.13%$227.23 (−12.69%)
Aug 27, 2026
5w ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$249.36 $271.12▲ +8.73%▲ +8.46%$227.23 (−8.87%)
Aug 19, 2026
6w ago
ANALYST-UPGRADE
BULLISH ★ 4/10
$259.62 $250.25▼ −3.61%▼ −3.22%$227.23 (−12.48%)
Aug 19, 2026
6w ago
Insider Buy
NEUTRAL ★ 3/10
$259.62 $250.25▼ −3.61%▼ −3.22%$227.23 (−12.48%)
Aug 13, 2026
7w ago
6-K
BULLISH ★ 7/10
$246.23 $254.81▲ +3.48%▲ +5.45%$227.23 (−7.72%)
Aug 13, 2026
7w ago
Press Release
BULLISH ★ 7/10
$246.23 $254.81▲ +3.48%▲ +5.45%$227.23 (−7.72%)
Aug 6, 2026
8w ago
6-K
BULLISH ★ 7/10
$249.85 $246.23▼ −1.45%▼ −2.66%$227.23 (−9.05%)
Aug 6, 2026
8w ago
Press Release
BULLISH ★ 7/10
$249.85 $246.23▼ −1.45%▼ −2.66%$227.23 (−9.05%)
Jul 15, 2026
11w ago
6-K
NEUTRAL ★ 2/10
$259.80 $252.66▼ −2.75%▼ −1.08%$227.23 (−12.54%)
Showing 10 of 29

US Market Status

Market Open — Closes in 3h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access